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Epilepsy is a common condition in the United States. It is estimated that 1.2% of the population
or 3.4 million people have epilepsy. This ﬁgure may be underestimated because of potential
repercussions and stigma in disclosing epilepsy.1 Studies have shown that people with epilepsy
are more likely to be unemployed or unable to work, have lower annual household incomes, be
obese and physically inactive, and be less likely to marry.2,3 People with epilepsy can have poor
overall health status, impaired intellectual and physical functioning, elevated risk of accidents
and injuries, and negative side eﬀects from antiseizure medications.2,3 It is estimated the annual
direct medical cost of epilepsy in the United States is $9.6 billion; combined with indirect costs,
the total rises to $15.5 billion yearly.2
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The American Academy of Neurology (AAN) created standardized quality measures with the
overarching goal to improve the delivery of care for patients with epilepsy for providers,
practices, and systems. In 2009, the ﬁrst set of epilepsy measures were released with an update
provided in 2014.4,5 Quality measures are not guidelines; however, they are formed using
guidelines, evidence-based medicine, and best practice consensus. Quality measures help us
understand how often health care services are provided consistent with current medical
knowledge. Measures are updated iteratively to reﬂect evidence and practice changes, as well as
to reﬂect limitations of data collection and analysis.
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The AAN reviews each measurement set for updates a minimum of every 3 years. In 2017, the
AAN seated a standing multidisciplinary Epilepsy Quality Measurement Set Work Group
(work group) charged with updating the measurement set. This work group will revisit the
epilepsy measures every 6 months, evaluating new evidence statements and new measures
released by other developers. As part of this process, epilepsy measure implementation and
performance data review will also occur to nimbly respond to emerging guidelines and
evidence.
During this initial review, the work group evaluated new evidence, 2014 epilepsy measure use
data, and other new measures released by other development groups that addressed care for
patients with epilepsy, such as the AAN’s Child Neurology and Universal Neurology Quality
Measure projects. The work group approved 6 measures and retired 6 measures from the 2014
update (table 1). Measure retirement occurs if evidence has changed, a gap in performance no
longer exists, feasibility concerns exist, or signiﬁcant edits are needed to the existing measure. It
does not mean the topic is no longer important. Full measure speciﬁcations are available online
at aan.com/practice/quality-measures/ and in appendix e-1, links.lww.com/WNL/A721.
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Glossary
AAN = American Academy of Neurology; CMS = Centers for Medicare & Medicaid Services; ICD-10 = International
Classiﬁcation of Diseases, Tenth Revision; MIPS = Merit-based Incentive Payment System; QOL = quality of life; QOLIE-10-P =
patient-weighted Quality of Life in Epilepsy Inventory-10.

Table 1 Epilepsy Quality Measurement Set 2017 update
Title

Numerator

Denominator

Exclusions
a

Counseling for Women of
Childbearing Potential
with Epilepsy

All females, including all individuals of
childbearing potential (aged 12–44 y)
with a diagnosis of epilepsy

Patients or caregivers counseled at
least once a year about how epilepsy and
its treatment may affect contraception
and/or pregnancy. Measure is met if
patient has documentation they are
premenstrual, postmenopausal,
surgically sterile, or reproductive organs
absent.

None

Comprehensive Epilepsy
Care Center Referral or
Discussion for Patients
with Intractable Epilepsy

Patients with an order for referral to
a comprehensive epilepsy care center,
who had a discussion of evaluation at
a comprehensive epilepsy care center, or
who received treatment at
a comprehensive epilepsy care center
during the measurement period

Patients diagnosed with intractable
epilepsy (see appendix of codes) or
patients diagnosed with epilepsy who
were prescribed 3 or more distinct
antiseizure medications in the past 2 y

None

Quality-of-Life
Assessment for Patients
with Epilepsy

Patients with age-appropriate,
condition-specific quality of life
assesseda at least once in the
measurement period

Patients aged 4 y and older diagnosed
with epilepsy

Patients who are unable or decline
to complete the instrument and for
these patients a caregiver is not
present to provide proxy report

Quality-of-Life Outcome
for Patients with Epilepsy

Patients whose most recent QOLIE-10-P
score is maintained or improved from
the prior QOLIE-10-P score obtained in
the measurement period

Patients aged 18 y and older diagnosed
with epilepsy who had 2 office visits
during the 2-y measurement period,
which occurred at least 4 wk apart

None

Depression and Anxiety
Screening for Patients
with Epilepsy

Patients aged 12 y and older diagnosed
with epilepsy

Patients with epilepsy who were
screened for both depressiona and
anxietya at every office visit

• Patients who are unable or decline
to complete epilepsy-specific
screening tool
• Patient has a diagnosis of
depression or anxiety on active
problem list

Seizure Frequency for
Patients with Epilepsy

All visits for patients with a diagnosis of
epilepsy

Patient visits with current seizure
frequencya documented for each seizure
type

• Caregiver is unavailable for a patient
who is noncommunicative or has an
intellectual disability
• Patient or caregiver declines to
report seizure frequency

Abbreviation: QOLIE-10-P = patient-weighted Quality of Life in Epilepsy Inventory-10.
The listed measures were approved by the work group. There is no requirement that all measures in the measurement set be used. Providers are encouraged
to identify the 1 or 2 measures that would be most meaningful for your patient populations and implement these measures to drive performance
improvement in practice.
a
Refer to appendix e-1 (links.lww.com/WNL/A721) for further definitions.

Opportunities for improvement
The work group initially identiﬁed 18 concepts for potential
measures. The AAN prioritized concepts that are supported
by the following criteria: strong evidence and guideline
statements, feasible to collect, and have a substantial link to
improved health care outcomes. Among the putative concepts, the work group prioritized development of measures
Supplemental Data
NPub.org/m0awph
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addressing (1) counseling for women of childbearing potential, (2) referral or discussion of referral to a comprehensive epilepsy care center for patients with intractable
(treatment-resistant) epilepsy, (3) quality-of-life (QOL)
outcome assessments, and (4) depression and anxiety
screening.
Counseling for women of
childbearing potential
Epilepsy has been linked to reduced fertility, increased pregnancy risks, and risks of malformations and behavioral abnormalities in the infant.6 Treatment of seizures with
Neurology.org/N
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antiseizure medications may alter hormone levels, render oral
contraceptives less eﬀective, and may interfere with embryonic
and fetal development.7–9 In addition, oral contraceptives may
lower AED levels thus making them less eﬀective.8 Counseling
and discussion for women with epilepsy can have important
and beneﬁcial eﬀects with the goal of reducing unplanned
pregnancies, birth and cognitive deﬁcits among infants, and
complications that can occur during pregnancy and delivery
for women with epilepsy.10–13 Guidelines and interventions
are available to assist in conveying this important information
as well as initiating interventions once the information is
conveyed12–16; however, gaps in providing such counseling to
women with epilepsy exist.17–19
Referral or discussion of referral to
a comprehensive epilepsy care center for
patients with intractable (treatmentresistant) epilepsy
Despite the strong evidence of superior outcomes among
those who receive epilepsy surgery and other specialized
services at comprehensive epilepsy centers, only a small
fraction of patients are referred within 2 years of developing
intractable epilepsy (treatment-resistant epilepsy), with years
of delay occurring before referral for epilepsy surgery.20–22
Contributors to the delay in referral include improper identiﬁcation of medication treatment resistance (intractability)
and gaps in knowledge related to epilepsy surgery guidelines.23 Evaluation and treatment at comprehensive epilepsy
centers can also lead to appropriate diagnosis for patients
without epilepsy, but with nonepileptic spells, in addition to
the utilization of specialized treatments including, for example, dietary therapy, neurostimulation, medical research
trials, and psychosocial supports for those with intractable
epilepsy.
Quality-of-life outcome assessments
Maintenance and improvement of QOL is a primary goal in
caring for a patient with epilepsy. Given the numerous psychological, cognitive, social, and physical challenges that
people with epilepsy face, health-related QOL is an essential
patient-centered outcome to assess.24–27 Patients and caregivers have signaled that this information is of value to them,
and the Centers for Medicare & Medicaid Services (CMS)
has recently developed plans to incorporate patient-reported
outcome data such as QOL assessments into their Meritbased Incentive Payment System (MIPS). Providers reported
that they preferred such instruments be used electronically to
collect patient-reported outcome measures on QOL and
other important screening areas.28
Depression and anxiety screening
People with epilepsy have high rates of psychiatric disorders,
with approximately 20% of patients reporting depression or
anxiety.29 Such comorbidities place patients with epilepsy at
higher risk of poor QOL,30,31 poor adherence to
medication,32,33 and increased risk of suicide.34 Antiseizure
medications can also themselves place patients at risk of
Neurology.org/N

mood-related changes. Screening for symptoms of depression
and anxiety in patients with epilepsy using a number of valid,
reliable screening instruments has been shown to be
eﬀective.31,35,36 Screening for depression and anxiety is imperative to identify patients with epilepsy potentially at risk
and in need of treatment. For example, treatment of mood
disorders can help mitigate the risk of development of moodrelated adverse events, including but not limited to loss of
work, decreased QOL, and suicide.37
Although measuring seizure frequency was thought to be
fraught with feasibility and validity issues, it is being recommended for continued inclusion. The ﬁeld will need to move
toward a more standardized capture of seizure frequency. The
work group notes that activity is being done in this area
through a Learning Healthcare Collaborative and hopes to
utilize these developments to enhance the seizure frequency
measure in future updates.

Methods
The AAN Quality and Safety Subcommittee approved
a modiﬁed, pilot measure development process for this update. Details of the full measure development process are
available online.38 The AAN seated a standing work group for
a 2-year term, and 2 nonvoting facilitators were seated to
provide methodologic support. The work group includes
physician, nursing, patient, and caregiver representatives from
professional associations and patient advocacy organizations
to ensure measures developed included input from all members of the health care team and other relevant stakeholders.
All members are required to disclose relationships with industry and other entities to avoid actual, potential, or perceived conﬂicts of interest. Individuals were instructed to
abstain from voting on individual measure concepts if a conﬂict was present.
The AAN anticipates this work group will revisit measures
every 6 months. The work group is charged with updating
measures as needed over the 2-year period and developing
supporting materials and implementation guides as
appropriate.
At the start of the project, existing guidelines, measures, and
evidence were identiﬁed. A comprehensive literature search
was conducted by a medical librarian identifying 852 abstracts
relevant to the topic since the last update in 2014. Following
review, 10 guidelines were located and became the basis of the
evidence for measure development. The AAN measure development process involves a modiﬁed Delphi review by the
work group to reach consensus on measures to be developed
prior to a 21-day public comment period and again following
reﬁnement after the public comment period.
The work group reviewed the eight 2014 epilepsy quality
measures and proposed 18 new measure concepts. The work
Neurology | Volume 91, Number 18 | October 30, 2018
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group rated concepts via a modiﬁed Delphi review based on
the following criteria: impact on improving care, feasibility to
collect data, and demonstrated link to improved patient
outcomes. The work group removed 5 concepts following
these ratings. To further winnow concepts, work group
members then ranked new measure concepts. This resulted in
8 additional concepts being dropped from development.
Work group discussions were held on the remaining 6 new
measure concepts. Two concepts were removed because of
feasibility concerns, and the QOL concept was split into
process and outcome measures speciﬁcations. Seven measures were retired and 5 new concepts approved following
work group votes. A 21-day public comment period was held.
Following and based on public comment, measure retirement
decisions were revisited. Based on public comments, the work
group voted to not retire the seizure frequency measure from
2014. Finally, the measure speciﬁcations were reﬁned, and the
work group, AAN’s Quality and Safety Subcommittee, AAN’s
Practice Committee, and AAN’s Board of Directors approved
the measurement set.

Results
The work group approved 6 measures (table 1). Full measurement speciﬁcations are available online at aan.com/
practice/quality-measures/ and in appendix e-1, links.lww.
com/WNL/A721. The 6 measures identiﬁed have strong
guideline statements or evidence to support numerator, denominator, and exclusion criteria. In addition, there are
known gaps in care where treatment and outcomes could be
improved. For process measures, a link or relationship to
improved health care outcomes exists.
Counseling for women of childbearing
potential with epilepsy
The women with epilepsy measure remains the one
epilepsy-speciﬁc measure available for use in CMS’s MIPS
program. The measure has been implemented in AAN’s
Axon Registry®. Based on feedback from Axon Registry
data, the speciﬁcations were updated to clarify which
counseling components are required to be compliant with
the measure. The measure now requires counseling on at
least 2 of 3 topics: (1) need for folic acid supplementation,
(2) drug-to-drug interactions with contraception medication, and (3) the potential antiseizure medication eﬀects(s)
on fetal/child development and/or pregnancy. The work
group discussed a proposal for patients to meet the measure
by folic acid prescription alone, but ultimately declined to
do so noting the intent of the measure is to increase
counseling. Patient representation as well as physician
members reported concern that females are often prescribed folic acid without understanding the rationale for
the prescription. The work group expanded the deﬁnition of
female gender to include LGBTQ+ patients who may be at
risk of unintended pregnancies. The work group eliminated
some exclusions and allowed for providers to meet the
832
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measure by documenting whether a patient is premenstrual,
postmenopausal, or surgically sterile, or their reproductive
organs are absent. This change was attributable to a low
capture rate of exclusions in practice, and it is hoped by
moving these to numerator criteria, documentation of these
conditions will improve.
Comprehensive epilepsy care center referral
or discussion for patients with
intractable epilepsy
The 2014 referral to comprehensive epilepsy center measure
was retired because of denominator feasibility concerns.
Speciﬁcally, the denominator required identifying individuals with failure of 2 antiseizure medications, but this is not
uniformly documented in the medical record. In addition,
some providers have a diﬃcult time identifying these
patients because of misunderstanding around the deﬁnition
of treatment resistance. The work group created a new
measure addressing discussion or referral to a comprehensive epilepsy care center. The denominator identiﬁed by
either (1) an ICD-10 diagnosis of intractable epilepsy
(treatment-resistant epilepsy) or (2) a diagnosis of epilepsy
and 3 or more distinct antiseizure medications prescribed in
the past 2 years will be more feasible to collect. The measurement set includes a list of antiseizure medications that
will be updated over time, and excluded rescue medications.
The numerator is met by an order for referral, discussion of
an evaluation, or receiving treatment during the calendar
year at a comprehensive epilepsy care center. By creating
a measure ensuring these patient populations are referred or
have comprehensive epilepsy care center services discussed,
it is anticipated that there will be an increase in appropriate
evaluations. Such an evaluation, multidisciplinary in nature,
would conﬁrm diagnostic accuracy and result in oﬀering of
eﬀective nondrug and nonsurgical treatment options, which
may include psychiatric, psychological, and social counseling
to address consequences of epilepsy. Diﬃculty understanding the deﬁnition for these patients exists, making
the identiﬁcation of these patients challenging. Validation of
the current measure will need to occur to determine whether
this is an eﬀective way to identify patients with treatmentresistant epilepsy.
Quality of life
The work group created a process and an outcome measure
for QOL for patients with epilepsy. The process measure
requires assessment with an age-appropriate, conditionspeciﬁc QOL assessment tool. A list of multiple assessment
tools is provided to meet individual provider and practice
needs. The outcome measure assesses maintenance or improvement on patients’ Quality of Life in Epilepsy (QOLIE10-P) scores in the measurement period. The validated
QOLIE-10-P was identiﬁed to allow comparability in scores
and ease of implementation particularly given the low likelihood of respondent fatigue with a brief survey of 10 questions.
As noted above, this measure was chosen in part because of its
meaningfulness to patients.
Neurology.org/N
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Depression and anxiety screening for patients
with epilepsy
A quality improvement measure screening annually for depression and anxiety was created. This measure will not be
submitted for use in accountability programs or the AAN’s
Axon Registry, as the measure does not include a follow-up
care component. A necessary ﬁrst step in assessing outcomes
is to ensure that patients are screened for anxiety and depression. As such, before implementing an outcome measure,
the work group thought that a requisite ﬁrst step is to routinely screen patients for symptoms of anxiety and/or depression so that proper diagnoses and treatment could be
initiated. Future measures may be developed to assess outcomes over time. The work group encourages providers to
implement the PHQ-2 (2-item Patient Health Questionnaire)
and GAD-2 (2-item Generalized Anxiety Disorder scale)
because they are brief, valid, and reliable tools.

likelihood of improving outcomes. Many lessons on feasibility
have been learned since the development of the 2009 measurement set. Some of the prior measures lacked speciﬁcity,
were infeasible, or were not likely to provide meaningful data
to drive improvement in practice. In addition, CMS phased
most of the epilepsy measures out of their Physician Quality
Reporting System and MIPS programs because of concerns
shared by the group including:
1.

2.

The work group reviewed performance data for the entire
2014 epilepsy measurement set, as well as current use in accountability programs. Six measures were retired (table 2). A
new measure was created for referral to a comprehensive
epilepsy center. The other 5 retired measures are listed below.
Retirement decisions should not be viewed to indicate value is
lacking in measuring these processes or concepts. The AAN is
of the belief no one measurement set can meet the measurement needs of all providers or patients and prioritizes
measure concepts based on speciﬁcity, feasibility, and

Seizure intervention was retired because of inability to
link documentation to improved outcomes and burdensome process requirements. The work group noted the
measure was dropped from use in CMS accountability
programs in 2017 because of low-level evidence and
failure to link the measure to improved care.
Etiology, seizure type, or syndrome was retired because
existing speciﬁcations had little eﬀect on quality
improvement eﬀorts. The work group noted the measure
was dropped from use in CMS accountability programs
in 2017 because of low-level evidence and failure to link
the measure to improved care. The work group could not
ﬁnd evidence to refute the failure to link to improved
patient outcomes. The work group noted it is diﬃcult to
assess 3 separate components without standardized
discrete data ﬁelds to ease data collection burdens. If
work in the ﬁeld of epilepsy can overcome this barrier,
future measure development in these areas will be
considered.

Table 2 Retired epilepsy quality measures
Title

Retirement rationalea

Seizure Intervention

Inability to link documentation to improved outcomes and burdensome process requirements.
The work group noted the measure was dropped from use in CMS accountability programs in
2017 because of low-level evidence and failure to link the measure to improved care.

Etiology, Seizure Type, or Epilepsy Syndrome

Specifications were not demonstrated to have a meaningful effect on quality improvement
efforts. The work group noted the measure was dropped from use in CMS accountability
programs in 2017 because of low-level evidence and failure to link the measure to improved care.

Querying and Intervention for Side Effects of
Antiseizure Therapy

Feasibility concerns noted as locating uniform data in a medical record was difficult.

Personalized Epilepsy Safety Issue and Education

The broad definition of education affected feasibility of abstraction from the medical record.
Potential counseling options were too broad to inform providers on meaningful interventions for
quality improvement efforts and because the definition of education was so broad there was no
meaningful performance gap to address.

Screening for Psychiatric or Behavioral Health
Disorders for Patients with Epilepsy

Specifications were overly broad and inclusive of numerous behavioral health conditions that
made abstraction from the medical record difficult. The work group planned to develop an
outcome measure addressing depression improvement. However, the work group determined
development of an outcome measure on this issue was not feasible given treatment is primarily
delivered by psychiatry, primary care physicians, or other treatment team members. The work
group developed a refined depression and anxiety screening measure with greater specificity for
quality improvement purposes.

Referral to Comprehensive Epilepsy Center

Feasibility concerns noted. The denominator required identifying individuals with failure of 2
antiseizure medications, and this is not uniformly documented in the medical record.

Abbreviation: CMS = Centers for Medicare & Medicaid Services.
These concepts will be retained for consideration in future updates. It is hoped documentation innovation will occur generating greater specificity in patient
records that lead to improved opportunities to capture measure specifications and drive change affecting patient outcomes. The American Academy of
Neurology prioritizes measure concepts with specificity, feasibility, link to outcomes, and strong evidence. The American Academy of Neurology limits the
number of measures released to reduce provider collection burden and to target testing and implementation resources for meaningful measures in practice.
a
Refer to appendix e-1 (links.lww.com/WNL/A721) for further details.

Neurology.org/N
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3.

4.

5.

Querying and interventions for side eﬀects of antiseizure
therapy was retired because of diﬃculty in locating
uniform data in a medical record aﬀecting feasibility
without use of a standard and consistent reporting
instrument or methodology.
Personalized epilepsy safety issue and education provided was retired as potential counseling options were
too broad to inform providers on meaningful interventions for quality improvement eﬀorts and because the
deﬁnition of education was so broad there was no
meaningful performance gap to address. The broad
deﬁnition of education aﬀected feasibility of abstraction
from the medical record.
Screening for psychiatric or behavioral health was retired
to reduce duplicative measures in the ﬁeld. The measure
was overly broad and inclusive of numerous behavioral
health conditions that made abstraction from the medical
record diﬃcult. The work group planned to develop an
outcome measure addressing depression improvement.
However, development of an outcome measure on this
issue was not feasible at this time given treatment is often
delivered outside the ﬁeld of neurology. The work group
developed a reﬁned depression and anxiety screening
measure with greater speciﬁcity for quality improvement
purposes.

Based on information collected during the public comment
period, the work group voted again on each individual measure regarding retirement. The work group voted not to retire
the seizure frequency measure following further discussion
and included the 2014 speciﬁcation of the measure to meet
user needs. The work group noted that the seizure frequency
measure has been retired from use in CMS accountability
programs because of lack of a gap in care with consistent highperformance rates. Reporting capture of seizure frequency is
standard of care, and there is an inability to link documentation of seizure frequency to improved outcomes. The work
group also noted there is a lack of speciﬁcity and uniformity in
collecting quantity of seizures across providers, resulting in
feasibility issues. Patient communication on this topic demonstrated that providers rarely inquired what seizure control
meant to patients.39 The Axon Registry has implemented the
measure through use of a data dictionary and search terms,
and the average performance rate for Axon users as of December 2017 is 27.92%. The work group will collaborate with
organizational partners and the many current Learning
Healthcare Collaborative eﬀorts evaluating this issue to update the speciﬁcations during future updates when additional
evidence supports standardization in documentation of seizure frequency.

Conclusion
This measure set represents the second update of an ongoing
eﬀort to provide individual providers, practices, and systems
with tools needed to drive performance improvement in
834
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epilepsy care. There is no requirement that providers use
every measure in the set. These measures have been primarily
developed to be used in quality improvement projects, and
providers are encouraged to identify the 1 or 2 measures that
would be most meaningful for their patient population and
implement these measures to drive improvement in practice.
The work group will be revisiting these decisions over time
and anticipates development and release of additional tools to
assist in the implementation of these measures into practice.
The work group will be able to respond to testing data, performance data, and new evidence such as the planned updates
to the AAN’s Women with Epilepsy guideline statements.
Select measures will be submitted for consideration in the
AAN’s Axon Registry, which is proving a useful tool for
providers to drive performance improvement in practice while
meeting American Board of Psychiatry and Neurology’s
Maintenance of Certiﬁcation Part IV requirements. It is anticipated once testing data have been obtained, measures may
be submitted for consideration in CMS’s MIPS program. In
addition, select private payers may utilize these measures to
track provider performance. It is important that providers
have access to epilepsy measures developed by multidisciplinary treatment team members to ensure that these performance measures are meaningful to providers and patients.
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Laganà AS, Triolo O, D’Amico V, et al. Management of women with epilepsy: from
preconception to post-partum. Arch Gynecol Obstet 2016;293:493–503.
Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management
issues for women with epilepsy—focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and
Therapeutics and Technology Assessment Subcommittee of the American Academy of
Neurology and American Epilepsy Society. Neurology 2009;73:133–141.
Harden CL, Hopp J, Ting TY, et al. Practice parameter update: management issues for
women with epilepsy—focus on pregnancy (an evidence-based review): obstetrical
complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American
Academy of Neurology and American Epilepsy Society. Neurology 2009;73:126–132.
Sabers A. Treatment guidelines: women of fertile age. Epileptology 2013;1:11–16.
Harden CL, Pennell PB, Koppel BS, et al. Practice parameter update: management issues
for women with epilepsy—focus on pregnancy (an evidence-based review): vitamin K,
folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee
and Therapeutics and Technology Assessment Subcommittee of the American Academy
of Neurology and American Epilepsy Society. Neurology 2009;73:142–149.
Mody SK, Haunschild C, Farala JP, et al. An educational intervention on drug
interactions and contraceptive options for epilepsy patients: a pilot randomized
controlled trial. Contraception 2016;93:77–80.
Moura LMVR, Yacaman Mendez D, De Jesus J, et al. Quality care in epilepsy:
women’s counseling and its association with folic acid prescription or recommendation. Epilepsy Behav 2015;44:151–154.
Fitzsimons M, Dunleavy B, O’Byrne P, et al. Assessing the quality of epilepsy care with
an electronic patient record. Seizure 2013;22:604–610.
George IC. How do you treat epilepsy in pregnancy? Neurol Clin Pract 2017;7:
363–371.
Jette N, Sander J, Keezer M. Surgical treatment for epilepsy: the potential gap between
evidence and practice. Lancet Neurol 2016;15:982–984.
Burneo J, Shariﬀ S, Liu K, et al. Disparities in epilepsy surgery among patients with
epilepsy in a universal health system. Neurology 2016;86:72–78.
Pieters H, Iwaki T, Vickrey B, et al. “It was ﬁve years of hell”: parental experiences of
navigating and processing the slow and arduous time to pediatric resective epilepsy
surgery. Epilepsy Behav 2016;62:276–284.
Roberts J, Hrazdil C, Wiebe S, et al. Neurologists’ knowledge of and attitudes toward
epilepsy surgery: a national survey. Neurology 2015;84:159–166.
Martin R, Vogtle L, Gilliam FFE. What are the concerns of older adults living with
epilepsy? Epilepsy Behav 2005;7:297–300.
Fayers P, Machin D. Quality of Life: The Assessment, Analysis and Interpretation of
Patient-Reported Outcomes, 2nd ed. New York: John Wiley & Sons; 2013.
Birbeck GL, Hays RD, Cui X, Vickrey BG. Seizure reduction and quality of life
improvements in people with epilepsy. Epilepsia 2002;43:535–538.

Neurology | Volume 91, Number 18 | October 30, 2018

Copyright ª 2018 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.

835

27.

28.

29.

30.
31.
32.

Vickrey BG, Berg AT, Sperling MR, et al Relationships between seizure severity and
health-related quality of life in refractory localization-related epilepsy. Epilepsia 2000;
41:760–764.
Katzan IL, Thompson NR, Dunphy C, Urchek J, Lapin B. Neurologic provider views
on patient-reported outcomes including depression screening. Neurol Clin Pract
2018;8:86–92.
Kroenke K, Spitzer RL, Williams JBW, et al. Anxiety disorders in primary care:
prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007;146:
317–325.
Spielberger CD, Gorsuch RL, Lushene RE. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press; 1970.
Marteau T, Bekker H. The development of a six-item short-form of the state scale of
the Spielberger State-Trait Anxiety Inventory (STAI). Br J Psychol 1992;31:301–306.
Pham T, Sauro KM, Patten SB, et al. The prevalence of anxiety and associated factors
in persons with epilepsy. Epilepsia 2017;58:e107–e110.

33.
34.
35.
36.
37.

38.

39.

Baca CB, Vickrey BG, Caplan R, et al. Psychiatric and medical comorbidity and quality
of life outcomes in childhood-onset epilepsy. Pediatrics 2011;128:e1531–1543.
Gur-Ozmen S, Leibetseder A, Cock HR, et al. Screening of anxiety and quality of life in
people with epilepsy. Seizure 2017;45:107–113.
Gilliam FG, Barry JJ, Hermann BP, et al. Rapid detection of major depression in
epilepsy: a multicentre study. Lancet Neurol 2006;5:399–405.
Mula M. Depression in epilepsy. Curr Opin Neurol 2017;30:180–186.
Mula M, Kanner AM, Schmitz B, et al. Antiepileptic drugs and suicidality: an expert
consensus statement from the Task Force on Therapeutic Strategies of the ILAE
Commission on Neuropsychobiology. Epilepsia 2013;54:199–203.
Quality and Safety Subcommittee. American Academy of Neurology Quality Measurement Manual 2017 Update. 2018. Available at: aan.com/policy-and-guidelines/
quality/quality-measures2/how-measures-are-developed/. Accessed March 16, 2018.
Stern JM, Cendes F, Gilliam F, et al. Neurologist-patient communication about epilepsy in the United States, Spain, and Germany. Neurol Clin Pract 2018;8:93–101.

Are You Ready to Maximize Your Medicare Reimbursement?
Use the AAN tools and resources to earn positive payments and avoid penalties under MIPS.
Take action today, visit AAN.com/view/QPP

Subspecialty Alerts by E-mail!
Customize your online journal experience by signing up for e-mail alerts related to your subspecialty or area of interest. Access
this free service by clicking on the “My Alerts” link on the home page. An extensive list of subspecialties, methods, and study
design choices will be available for you to choose from—allowing you priority alerts to cutting-edge research in your field!

Sign Up for the AAN’s Axon Registry

®

The AAN encourages its US members to show their interest in participating in the Axon Registry by signing up today.
Use the Axon Registry to:
• Simplify reporting requirements under MACRA’s Quality Payment Program and avoid penalties while reducing your administrative
burden
• Meet your MOC Part IV requirements and waive up to eight credits of Part II Self-Assessment
• Choose from 22 AAN neurology-specific quality measures that fit your practice
• Use data to understand your practice and identify where improvements can be made to patient care
• Manage your patients at a population level; look at a specific group of patients based on conditions, risk factors, demographics or outcome
• Demonstrate your value to payers when negotiating reimbursement
• Enjoy multi-year, fee-free access when you sign the agreements and integrate your EHR with the registry

Learn more at AAN.com/view/Axon and send your questions to registry@aan.com.

836

Neurology | Volume 91, Number 18 | October 30, 2018

Neurology.org/N

Copyright ª 2018 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.

